Incretin and islet hormonal responses to fat and protein ingestion in healthy men.
暂无分享,去创建一个
C. Deacon | B. Ahrén | R. Carr | M. S. Winzell | M. Larsen | Katarina Jelic | O. Lindgren
[1] D. Drucker,et al. Biology of incretins: GLP-1 and GIP. , 2007, Gastroenterology.
[2] J. Holst,et al. Pharmacodynamics of Vildagliptin in Patients With Type 2 Diabetes During OGTT , 2007, Journal of clinical pharmacology.
[3] J. Holst,et al. Metabolic effects of amino acid mixtures and whey protein in healthy subjects: studies using glucose-equivalent drinks. , 2007, The American journal of clinical nutrition.
[4] C. Deacon,et al. Glucose-induced incretin hormone release and inactivation are differently modulated by oral fat and protein in mice. , 2006, Endocrinology.
[5] M. Prentki,et al. Fatty acid signaling in the beta-cell and insulin secretion. , 2006, Diabetes.
[6] J. Holst. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005 , 2006, Diabetologia.
[7] J. Foley,et al. Alpha cell function in health and disease: influence of glucagon-like peptide-1 , 2005, Diabetologia.
[8] C. Deacon,et al. What do we know about the secretion and degradation of incretin hormones? , 2005, Regulatory Peptides.
[9] P. Brubaker,et al. Nutrient, neural and endocrine control of glucagon-like peptide secretion. , 2004, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[10] J. Holst,et al. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? , 2004, Expert opinion on investigational drugs.
[11] M. Camilleri,et al. The gastrointestinal tract and glucose tolerance , 2004, Current opinion in clinical nutrition and metabolic care.
[12] B. Ahrén. Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice. , 2004, American journal of physiology. Regulatory, integrative and comparative physiology.
[13] K. Frayn,et al. Vagal stimulation exaggerates the inhibitory ghrelin response to oral fat in humans. , 2004, The Journal of endocrinology.
[14] W. Creutzfeldt,et al. New developments in the incretin concept , 1985, Diabetologia.
[15] J. Holst,et al. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine , 2003, Regulatory Peptides.
[16] J. Holst,et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia , 2003, Diabetologia.
[17] E. Husebye,et al. Gastric emptying: the validity of the paracetamol absorption test adjusted for individual pharmacokinetics , 2001, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[18] K. Frayn,et al. Carbohydrate and fat have different effects on plasma leptin concentrations and adipose tissue leptin production. , 2001, Clinical science.
[19] J. Holst,et al. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. , 2000, The Journal of clinical endocrinology and metabolism.
[20] T. Dakka,et al. Peptide YY, Glucagon-Like Peptide-1, and Neurotensin Responses to Luminal Factors in the Isolated Vascularly Perfused Rat Ileum. , 1998, Endocrinology.
[21] B. Ahrén. Glucagon‐like peptide‐1 (GLP‐1): A gut hormone of potential interest in the treatment of diabetes , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.
[22] T. Dakka,et al. Peptide YY, glucagon-like peptide-1, and neurotensin responses to luminal factors in the isolated vascularly perfused rat ileum. , 1998, Endocrinology.
[23] A. Niijima,et al. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. , 1996, The American journal of physiology.
[24] J. Holst,et al. Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects , 1995, Diabetes.
[25] J. Holst,et al. Physiological augmentation of amino acid-induced insulin secretion by GIP and GLP-I but not by CCK-8. , 1995, The American journal of physiology.
[26] B. Göke,et al. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. , 1995, Digestion.
[27] J. Holst,et al. Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans , 1994, Diabetes.
[28] V. Marks,et al. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. , 1993, The Journal of endocrinology.
[29] D. Kelley,et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. , 1992, The New England journal of medicine.
[30] H. Mekhjian,et al. Localization of gastric inhibitory polypeptide release by intestinal glucose perfusion in man. , 1977, Gastroenterology.
[31] H. Mekhjian,et al. Stimulation of secretion of gastric inhibitory polypeptide and insulin by intraduodenal amino acid perfusion. , 1976, Gastroenterology.
[32] I. Cleator,et al. Release of immunoreactive gastric inhibitory polypeptide (IR-GIP) by oral ingestion of food substances. , 1975, American journal of surgery.
[33] J. Brown,et al. Gastric inhibitory polypeptide (GIP) stimulation by oral glucose in man. , 1974, The Journal of clinical endocrinology and metabolism.